NULISAseq CNS Disease Panel 120 Expanded with Blood-Based Brain-Derived pTau Assays
Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 to include highly sensitive, blood-based assays.
Read MorePosted by Chris Wolski | May 16, 2025 | Dementias & Alzheimer’s |
Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 to include highly sensitive, blood-based assays.
Read MorePosted by Chris Wolski | Apr 7, 2025 | Emerging & Zoonotic Diseases |
The Last of Us returns, adding scientific realism to its zombie apocalypse, portraying fungal infections more in line with scientific fact.
Read MorePosted by Chris Wolski | Dec 18, 2024 | Computing Systems |
Cloud-based LIS solutions are becoming popular in the U.S., offering benefits like flexibility and scalability.
Read MorePosted by Andy Lundin | Nov 19, 2024 | Sexually Transmitted Diseases |
NOWDiagnostics has launched the First To Know Syphilis Test, an FDA-authorized over-the-counter syphilis test in the U.S.
Read MorePosted by Andy Lundin | Nov 4, 2024 | Sexually Transmitted Diseases |
WHO has granted Cepheid’s Xpert Mpox test Emergency Use Listing, enabling rapid, point-of-care mpox detection to support outbreak management.
Read More